DOCSLIB.ORG

Subject Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Subject Index Subject Index active metabolites 212 Brief Psychiatric Rating Scale (BPRS) adenylate cyclase 82 131 adenylcyclase 9 4-bromo-2,5-dimethoxyphenyliso- adverse drug reactions 238 propylamine 15 AJ76 82 buproprion 174,190 akathesia 138 -, dose-effect relationship 174 akinesia 131 -, prediction of response 174 alcohol abuse 212 buspirone 52 alprazolam 111, 190 amisulpride 70,82 cardiovascular toxicity 163 amitriptyline 149, 163, 199,212,253 carpipramine 82 amperozide 70 chlorpromazine 70,138,199,212,230 amphetamine 124 citalopram 174,190,199 amoxapine 253 clinical response 149,253 anticholinergic effects 163 clomipramine 163, 190, 199,212 antidepressant plasma levels 238 clopenthixol 101 antidepressant, mechanism of action 38 clozapine 52,70,82, 101, 131,212 antidepressants 149, 190, 212, 238, 253 CNS-toxicity 163 antiparkinsonian medication 131 codeine 199 antipsychotic clinical response 138,253 compliance 174 antipsychotic dose 138 computer graphics 1 antipsychotic drugs 70, 82, 124, 246 concentration response 174 -, dopamine receptor affinity 70 concentration-effect relationships 131, -, serotonergic effects 70 174,212 -, serotonin receptor affinity 70 confusion 163 antipsychotic efficacy 124 cyanopindolol 9 anxiety 52 CYP2D6 199, 238 anxiolytic/antidepressant 52 - gene 199 anxiolytics 38 cytochrome P450 199 atypical antipsychotic drugs 70, 82 autoreceptors 38 Danish University Antidepressant Group azapirones 52 (DUAG) 190 debrisoquine 199,212,230,238 benzamide 70, 82, 101 delirium 163 benzodiazepine 138 delusions 131 beta-adrenergic receptors, cloning 9 depot neuroleptics 212 -, ligand binding 9 depression 131, 149 -, molecular characterization 9 -, bipolar 149 -, regulation 9 -, neurotic 149 -, structure 9 -, psychotic 149 -, subtypes 9 -, serotonin 38 beta2-adrenergic receptors -, treatment 149 biochemical basis 101 -, unipolar 149 blunted affect 131 desipramine 149, 163, 199,212,230 266 Subject Index dexamethasone test 149 genetic polymorphism 199 diagnostic heterogeneity 124 genetics 124 diazepam 199 genotypes 199 difludazine 101 genotyping 199 dopamine 1, 82 gepirone 38 - auto receptor 82 glutamate 124 - Dl receptor 1,82 - D2 receptor 1,82,94, 124, 138 hallucinations 131 - D3 receptor 82 hallucinogenic effects 52 - receptor antagonists 131 haloperidol 70, 101, 138, 199,212,230, dose binding 111 246 dose equivalency 131 Hamilton Depression Scale (HDS) 190 dose response 174 heterogeneity, schizophrenia 124 dose-effect relationship 163, 174 high pressure liquid chromatography dose-effect study 163 (HPLC) 212 drop-out 190 HVA, plasma 124 - rates 190 drug development 111 idazoxan 111 drug efficacy 124 125I-iodocyanopindolol 15 drug interaction 199 imipramine 163, 190, 199, 212, 238, 253 drug level monitoring 163 - in depression 163 drug metabolism 199 - in neuropathy pain 163 - in the elderly 238 - in nocturnal enuresis 163 drug metabolites 174 immunoassays 212 drug oxidations 199 individual dose adjustment 190 drug testing 111 interethnic differences 199,212 -, animal models 111 interindividual differences 199,230 -, physiological models 111 interindividual variability 212 drug trials 190 interrater reliability 190 drug-induced Parkinsonism 131 iodocyanopindolol 15 DSM-III 190 ipsapirone 38 DSM-I1I-R 149 isocarboxazide 149 dysthymia 149 dystonia 101 ketanserin 15 elderly 238 large ventricles schizophrenia 124 elderly population 238 levomepromazine 199,212,230,246 electroconvulsive shock 149 ligand interaction 1 extensive metabolizers (EM) 199,230, limbic system 82 238 liver insufficiency 212 extrapyramidal effects 238 low drug doses 163 extrapyramidal side effects 101 extrapyramidal syndromes 70, 94, 101 m-chlorophenylpiperazine (m-CPP) 52 extrapyramidal system 82 MAO-inhibitors 149 maprotiline 149 fixed dose 163, 190 maximal tolerated dose 111 flexible dose 163, 190 melperone 70, 101 fluoxetine 149, 199, 212, 253 mephenytoin 199,238 flupenthixol 212 mesulergine 15 fluperlapine 70 metabolic ratios 199 fluphenazine 131, 138, 163, 199,212 metabolites 174 fluspirilene 131 2-methylserotonin 70 fluvoxamine 149,174,199,253 mianserin 9, 199 fusaric acid 111 moclobemide 190, 199 molecular dynamics simulations 1 G protein 1,26,38,82 molecular electrostatic potentials 1 gas-liquid chromatography 212, 246 molecular mechanisms 1 Subject Index 267 molecular modeling 1 radioreceptor assay 212 rating scales 174 negative symptoms 131 receptor amino acid sequence 82 neuroleptic treatment 131 receptor heterogeneity 52 neuroleptics 199,212,230,246 receptor localization 26 Newcastle inventory 190 receptor mRNA 82 non-complicance 163, 190,212 receptor occupancy 70 nortriptyline 163, 190, 212 receptor ontogeny 26 receptor structure 1 obsessive-compulsive agoraphobia 149 receptors 1 obsessive compulsive disorder (OCD) 52 reduced haloperidol 212, 230 odansetron 38 remoxipride 70,82,101,199 8-0H-DPAT 38 response rate 163 orthostatism 163 reversible MAO inhibitors 190 oxprenolol 15 risperidone 101 ritanserin 15,52, 70, 101 panic disorder 52 parachlorophenylalinine (PCP A) 111 paroxetine 163, 174, 190, 199,253 s-adenosyl-methionine 111 - binding 26 s-mephenytoin 199,230 penfluridol 131 S21D2 antagonist ratio 70, 101 pergolide 82 Scale for the Assessment of Negative perphenazine 199,212,230 Symptoms (SANS) 131 pharmacogenetics 199 SCH 23390 101 pharmacokinetics 138,174 schizophrenia 82,124,131,138 phenothiazines 212, 238 - subtypes 124 phenotypes 199 sedation 163 phenotyping 163, 199 seizures 174 phospholipase C 26 selective serotonin reuptake inhibitors pimozide 70, 82, 131 (SSRI) 190 pipothiazine 82 serotonin auto receptors 38 placebo 253 serotonin receptors 1,15,38,70 plasma concentrations 246 -, cloning 15,70 plasma level monitoring 199,212,253 -, function 15 plasma levels, neuroleptics 138 -, ligand binding 15 plasma prolactin levels 70 -, molecular characterization 15 polymorphic metabolism 212 -, subtypes 15,52 poor metabolizers (PM) 199,212,230, serotonin reuptake inhibitors 38, 174, 199 238 serotonin transport 38 Positive and Negative Symptom Scale serotonin 5-HTA receptor 26 (PANSS) 131 serotonin 5-HT1A receptor 1,38,52 positive symptoms 131 serotonin 5-HTlB receptor 38,52 positron emission tomography 94, 124 serotonin 5-HT1C receptor 26, 52 post-psychotic depression 131 serotonin 5-HTm receptor 26,38,52 prediction of steady-state concentrations serotonin 5-HTlE receptor 52 212 serotonin 5-HT2 receptor 1,38,52 prolactin 124 serotonin 5-HT3 receptor 26,52 propranolol 9,38 serotonin 5-HT4 receptor 26,52 protein kinase C 111 sertraline 174, 199,253 psychomotor retardation 131 serum drug concentrations 190 publication bias 190 setoperone 101 sparteine 199,212,230 quinerolane 82 spiperone 15 quinperole 82 spontaneous recovery 163 steady-state plasma levels 230,246 raclopride 70, 101 stereospecific metabolism 212 [llC]raciopride 94 sulpiride 70,82, 101, 124 268 Subject Index tardive dyskinesia 238 type-l error 163 tefludazine 101 type-2 error 163 therapeutic drug monitoring 199,246 tyrosine transport 124 therapeutic index 174 therapeutic range 163 UH232 82 thioridazine 70, 199,212,230 underdosing 163 three-dimensional structure 1 1L99 82 voice analysis 131 toxicity 174 trazedone 253 whole blood concentrations 212 tricyclic antidepressant efficacy 149 within-patients variability 246 tricyclic antidepressants (TCA) 163,174, 190,199,212,238 zimelidine 149, 174 tryptophan hydroxylase 52 zuclopenthixol 212, 230 .
Load more

Recommended publications
  • Pindolol of the Activation of Postsynaptic 5-HT1A Receptors
    Potentiation by (-)Pindolol of the Activation of Postsynaptic 5-HT1A Receptors Induced by Venlafaxine Jean-Claude Béïque, Ph.D., Pierre Blier, M.D., Ph.D., Claude de Montigny, M.D., Ph.D., and Guy Debonnel, M.D. The increase of extracellular 5-HT in brain terminal regions antagonist WAY 100635 (100 ␮g/kg, i.v.). A short-term produced by the acute administration of 5-HT reuptake treatment with VLX (20 mg/kg/day ϫ 2 days) resulted in a inhibitors (SSRI’s) is hampered by the activation of ca. 90% suppression of the firing activity of 5-HT neurons somatodendritic 5-HT1A autoreceptors in the raphe nuclei. in the dorsal raphe nucleus. This was prevented by the The present in vivo electrophysiological studies were coadministration of (-)pindolol (15 mg/kg/day ϫ 2 days). undertaken, in the rat, to assess the effects of the Taken together, these results indicate that (-)pindolol coadministration of venlafaxine, a dual 5-HT/NE reuptake potentiated the activation of postsynaptic 5-HT1A receptors inhibitor, and (-)pindolol on pre- and postsynaptic 5-HT1A resulting from 5-HT reuptake inhibition probably by receptor function. The acute administration of venlafaxine blocking the somatodendritic 5-HT1A autoreceptor, but not and of the SSRI paroxetine (5 mg/kg, i.v.) induced a its postsynaptic congener. These results support and extend suppression of the firing activity of dorsal hippocampus CA3 previous findings providing a biological substratum for the pyramidal neurons. This effect of venlafaxine was markedly efficacy of pindolol as an accelerating strategy in major potentiated by a pretreatment with (-)pindolol (15 mg/kg, depression.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • FDA Approved Drugs with Broad Anti-Coronaviral Activity Inhibit SARS-Cov-2 in Vitro
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.25.008482; this version posted March 27, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro Stuart Weston1, Rob Haupt1, James Logue1, Krystal Matthews1 and Matthew B. Frieman*1 1 - Department of Microbiology and Immunology, University of Maryland School of Medicine, 685 W. Baltimore St., Room 380, Baltimore, MD, 21201, USA *Corresponding author. Email: [email protected] Key words: SARS-CoV-2, nCoV-2019, COVID-19, drug repurposing, FDA approved drugs, antiviral therapeutics, pandemic, chloroquine, hydroxychloroquine AbstraCt SARS-CoV-2 emerged in China at the end of 2019 and has rapidly become a pandemic with over 400,000 recorded COVID-19 cases and greater than 19,000 recorded deaths by March 24th, 2020 (www.WHO.org) (1). There are no FDA approved antivirals or vaccines for any coronavirus, including SARS-CoV-2 (2). Current treatments for COVID-19 are limited to supportive therapies and off-label use of FDA approved drugs (3). Rapid development and human testing of potential antivirals is greatly needed. A potentially quicker way to test compounds with antiviral activity is through drug re-purposing (2, 4). Numerous drugs are already approved for use in humans and subsequently there is a good understanding of their safety profiles and potential side effects, making them easier to test in COVID-19 patients.
    [Show full text]
  • The Role of the Serotonergic System and the Effects of Antidepressants During Brain Development Examined Using in Vivo Pet Imaging and in Vitro Receptor Binding
    From THE DEPARTMENT OF CLINICAL NEUROSCIENCE Karolinska Institutet, Stockholm, Sweden THE ROLE OF THE SEROTONERGIC SYSTEM AND THE EFFECTS OF ANTIDEPRESSANTS DURING BRAIN DEVELOPMENT EXAMINED USING IN VIVO PET IMAGING AND IN VITRO RECEPTOR BINDING Stal Saurav Shrestha Stockholm 2014 Cover Illustration: Voxel-wise analysis of the whole monkey brain using the PET radioligand, [11C]DASB showing persistent serotonin transporter upregulation even after more than 1.5 years of fluoxetine discontinuation. All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Universitetsservice-AB © Stal Saurav Shrestha, 2014 ISBN 978-91-7549-522-4 Serotonergic System and Antidepressants During Brain Development To my family Amaze yourself ! Stal Saurav Shrestha, 2014 The Department of Clinical Neuroscience The role of the serotonergic system and the effects of antidepressants during brain development examined using in vivo PET imaging and in vitro receptor binding AKADEMISK AVHANDLING som för avläggande av medicine doktorsexamen vid Karolinska Institutet offentligen försvaras i CMM föreläsningssalen L8:00, Karolinska Universitetssjukhuset, Solna THESIS FOR DOCTORAL DEGREE (PhD) Stal Saurav Shrestha Date: March 31, 2014 (Monday); Time: 10 AM Venue: Center for Molecular Medicine Lecture Hall Floor 1, Karolinska Hospital, Solna Principal Supervisor: Opponent: Robert B. Innis, MD, PhD Klaus-Peter Lesch, MD, PhD National Institutes of Health University of Würzburg Department of NIMH Department
    [Show full text]
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Mechanisms of Action of Antipsychotic Drugs Of
    302 Current Neuropharmacology, 2009, 7, 302-314 Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I R. Miller* Otago Centre for Theoretical Studies in Psychiatry and Neuroscience (OCTSPAN), Department of Anatomy and Struc- tural Biology, School of Medical Sciences, University of Otago, P.O.Box 913, Dunedin, New Zealand Abstract: Many issues remain unresolved about antipsychotic drugs. Their therapeutic potency scales with affinity for dopamine D2 receptors, but there are indications that they act indirectly, with dopamine D1 receptors (and others) as pos- sible ultimate targets. Classical neuroleptic drugs disinhibit striatal cholinergic interneurones and increase acetyl choline release. Their effects may then depend on stimulation of muscarinic receptors on principle striatal neurones (M4 recep- tors, with reduction of cAMP formation, for therapeutic effects; M1 receptors for motor side effects). Many psychotic pa- tients do not benefit from neuroleptic drugs, or develop resistance to them during prolonged treatment, but respond well to clozapine. For patients who do respond, there is a wide (>ten-fold) range in optimal doses. Refractoriness or low sensitiv- ity to antipsychotic effects (and other pathologies) could then arise from low density of cholinergic interneurones. Clozap- ine probably owes its special actions to direct stimulation of M4 receptors, a mechanism available when indirect action is lost. Key Words: Antipsychotic drugs, neuroleptic drugs, cholinergic interneurones, D1 receptors, D2 receptors, muscarinic M1 receptors, muscarinic M4 receptors, neuroleptic threshold, atypical antipsychotic agents. 1. INTRODUCTION these drugs. Guidelines for dosage, and dose equivalences between different drugs have been based on group averages The first antipsychotic drug - chlorpromazine - was dis- derived from dose-finding trials.
    [Show full text]
  • Modulation of Dialysate Levels of Dopamine, Noradrenaline
    Modulation of Dialysate Levels of Dopamine, Noradrenaline, and Serotonin (5-HT) in the Frontal Cortex of Freely-Moving Rats by (-)-Pindolol Alone and in Association with 5-HT Reuptake Inhibitors: Comparative Roles b of -Adrenergic, 5-HT1A, and 5-HT1B Receptors Alain Gobert, Ph.D. and Mark J. Millan, Ph.D. (-)-Pindolol, which possesses significant affinity for 5-HT1A, involved. (-)-Pindolol potentiated the increase in FCX levels b 5-HT1B, and 1/2-adrenergic receptors (AR)s, dose- of 5-HT elicited by the 5-HT reuptake inhibitors, fluoxetine dependently increased extracellular levels of dopamine and duloxetine, and also enhanced their ability to elevate (DA) and noradrenaline (NAD) versus 5-HT, in dialysates FCX levels of DA—though not of NAD. In contrast to of the frontal cortex (FCX), but not accumbens and (-)-pindolol, betaxolol and ICI118,551 did not affect the striatum, of freely-moving rats. In distinction, the actions of fluoxetine, whereas both WAY100,635 and b preferential 1-AR antagonist, betaxolol, and the SB224,289 potentiated the increase in levels of 5-HT—but b preferential 2-AR antagonist, ICI118,551, did not increase not DA or NAD levels—elicited by fluoxetine. In basal levels of DA, NAD, or 5-HT. Further, they both dose- conclusion, (-)-pindolol modulates, both alone and together dependently and markedly blunted the influence of with 5-HT reuptake inhibitors, dopaminergic, adrenergic, (-)-pindolol upon DA and NAD levels. The selective 5-HT1A and serotonergic transmission in the FCX via a complex b receptor antagonist, WAY100,635, slightly attenuated the pattern of actions at 1/2-ARs, 5-HT1A, and 5-HT1B (-)-pindolol-induced increase in DA and NAD levels, while receptors.
    [Show full text]
  • Achat Viagra Puissant ### Ablation Prostate Et Viagra >>> Kvadridze.Github.Io
    Viagra est indiquée pour le traitement de la dysfonction érectile masculine. >>> ORDER NOW <<< Achat viagra puissant Tags: ordonnance de viagra combien de temps dur viagra comment peut on se procurer du viagra efficacité viagra générique un site fiable pour acheter du viagra le viagra sur ordonnance danger dacheter du viagra sur internet prix cachet viagra combien coute le viagra au maroc le rôle de viagra peut acheter du viagra sans ordonnance quesque cest viagra composition de viagra acheter viagra paris sans ordonnance comment se procurer viagra sans ordonnance comment reconnaitre le faux viagra quand faut il prendre viagra comment acheter du viagra au quebec lancement du viagra quest ce que cest le viagra viagra pfizer mode demploi les conséquences du viagra edex plus viagra comment prendre de viagra forum viagra pas cher commande de viagra en ligne meme effet que viagra prendre la moitié dun viagra experience viagra femme A vaginal ring can slip out of the vagina. In the event of overdosage, general symptomatic and achat viagra puissant measures are indicated as required Resistance to azithromycin may be inherent or acquired. Comments: Take one pill a day. Ca 20 minuter senare börjar mina kollegor droppa in i ordningen: Susanne, Britt, Emma, Nina, Gunnel, Eva och sist Barbro. Epidemiologic investigations of this outbreak demonstrated that individuals in close contact with the index case or with exposure to poultry were at risk of being infected. 25 mg pour femme viagra cherche 2 weeks or until I "felt" like I could go lower. It might take a while to adapt to it, since it will lower your blood pressure.
    [Show full text]
  • Antipsychotics
    The Fut ure of Antipsychotic Therapy (page 7 in syllabus) Stepp,,hen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry Universityyg of California, San Diego School of Medicine Honorary Visiting Senior Fellow, Cambridge University, UK Sppyonsored by the Neuroscience Education Institute Additionally sponsored by the American Society for the Advancement of Pharmacotherapy This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. Copyright © 2011 Neuroscience Education Institute. All rights reserved. Individual Disclosure Statement Faculty Editor / Presenter Stephen M. Stahl, MD, PhD, is an adjunct professor in the department of psychiatry at the University of California, San Diego School of Medicine, and an honorary visiting senior fellow at the University of Cambridge in the UK. Grant/Research: AstraZeneca, BioMarin, Dainippon Sumitomo, Dey, Forest, Genomind, Lilly, Merck, Pamlab, Pfizer, PGxHealth/Trovis, Schering-Plough, Sepracor/Sunovion, Servier, Shire, Torrent Consultant/Advisor: Advent, Alkermes, Arena, AstraZeneca, AVANIR, BioMarin, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CeNeRx, Cypress, Dainippon Sumitomo, Dey, Forest, Genomind, Janssen, Jazz, Labopharm, Lilly, Lundbeck, Merck, Neuronetics, Novartis, Ono, Orexigen, Otsuka, Pamlab, Pfizer, PGxHealth/Trovis, Rexahn, Roche, Royalty, Schering-Plough, Servier, Shire, Solvay/Abbott, Sunovion/Sepracor, Valeant, VIVUS, Speakers Bureau: Dainippon Sumitomo, Forest, Lilly, Merck, Pamlab, Pfizer, Sepracor/Sunovion, Servier, Wyeth Copyright © 2011 Neuroscience Education Institute. All rights reserved. Learninggj Objectives • Differentiate antipsychotic drugs from each other on the basis of their pharmacological mechanisms and their associated therapeutic and side effects • Integrate novel treatment approaches into clinical practice according to best practices guidelines • Identify novel therapeutic options currently being researched for the treatment of schizophrenia Copyright © 2011 Neuroscience Education Institute.
    [Show full text]